Publication Date

Fall 2019

Advisor(s) - Committee Chair

Kevin Williams (Director), Blairanne Williams, and Lester Pesterfield

Degree Program

Department of Chemistry

Degree Type

Master of Science

Abstract

Monofunctional platinum(II) complexes, such as phenanthriplatin and pyriplatin, have notably different characteristics from the bifunctional anticancer complexes, such as cisplatin and oxaliplatin, which have detrimental toxicities and resistance associated with them. The unique properties of the monofunctional complexes may be exploited to target cancer cells without producing the toxic side effects associated with the current FDA-approved platinum-based anticancer drugs. To advance the understanding of these monofunctional platinum(II) complexes, this study replaced the chloride leaving ligand with an acetate group, which should increase solubility and alter the rate of reactivity with key amino acid and nucleotide targets. Phenanthriplatin and pyriplatin compounds were reacted with silver acetate to form insoluble silver chloride and the desired complex. Proton nuclear magnetic resonance (1H NMR) spectroscopy was used to characterize the new complexes and conduct kinetic assays with guanosine 5'-monophosphate (5’-GMP). A rate constant of 2.9 (± 0.7) x 10-2 M-1s-1 was determined for the reaction between pyriplatin and 5’-GMP, previously. A preliminary rate constant of 1.8 (± 0.1) x 10-2 M-1s-1 was determined for the newly synthesized cis-[Pt(NH3)2(py)OAc]+ complex with 5’-GMP. Ligand exchange kinetics directly influences the anticancer activity and toxicity of platinum drugs. Initial results indicate that the solubility is increased, and the rate of reaction is decreased by the acetate ligand.

Disciplines

Biochemistry | Inorganic Chemicals | Inorganic Chemistry

Available for download on Wednesday, November 25, 2020

Share

COinS